Exacerbation of schizophrenia by varenicline [7]

American Journal of Psychiatry

Volumn 164, Issue 8, 2007, Pages 1269-

  Freedman, Robert ^a,b  

^a Department of Veterans Affairs ^*

^b DEPARTMENT OF VETERANS AFFAIRS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NICOTINE; TIOTIXENE; VARENICLINE;

ADULT; CASE REPORT; CHEWING GUM; CIGARETTE SMOKING; CLINICAL FEATURE; FEMALE; HUMAN; LETTER; PRESCRIPTION; PRIORITY JOURNAL; RECURRENT DISEASE; REMISSION; SCHIZOPHRENIA; SMOKING CESSATION; TOBACCO DEPENDENCE; TREATMENT DURATION;

ACUTE DISEASE; BENZAZEPINES; COGNITION DISORDERS; COMORBIDITY; FEMALE; HUMANS; MIDDLE AGED; NICOTINE; QUINOXALINES; RECURRENCE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SELF MEDICATION; SMOKING; SMOKING CESSATION;

EID: 34548071446     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.ajp.2007.07020326     Document Type: Letter

References (3)

1. William JM, Foulds J: Successful tobacco dependence treatment in schizophrenia. Am J Psychiatry 2007; 164:222-227
2. Gonzales D, Rennard SI, Nides M, Oncken C, Azoulay S, Billing CB, Watsky EJ, Gong J, Williams KE, Reeves KR, for the Varenicline Phase 3 Study Group: Varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. J Am Med Assoc 2006; 296:47-55
3. Olincy A, Harris JG, Johnson LL, Pender V, Kongs S, Allensworth, Ellis J, Zerbe GO, Leonard S, Stevens KE, Stevens JO, Martin L, Adler LE, Soti F, Kem WR, Freedman R: Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia. Arch Gen Psychiatry 2996; 63:630-638